CN101636164A - 干眼症的治疗 - Google Patents

干眼症的治疗 Download PDF

Info

Publication number
CN101636164A
CN101636164A CN200780049235A CN200780049235A CN101636164A CN 101636164 A CN101636164 A CN 101636164A CN 200780049235 A CN200780049235 A CN 200780049235A CN 200780049235 A CN200780049235 A CN 200780049235A CN 101636164 A CN101636164 A CN 101636164A
Authority
CN
China
Prior art keywords
composition
progestin
pharmaceutically acceptable
concentration
acceptable carrier
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200780049235A
Other languages
English (en)
Chinese (zh)
Inventor
C·G·康纳
C·海纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Southern College of Optometry
Original Assignee
Southern College of Optometry
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Southern College of Optometry filed Critical Southern College of Optometry
Publication of CN101636164A publication Critical patent/CN101636164A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Eyeglasses (AREA)
CN200780049235A 2006-12-05 2007-12-05 干眼症的治疗 Pending CN101636164A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/634,347 US20080132475A1 (en) 2006-12-05 2006-12-05 Treatment for dry eye
US11/634,347 2006-12-05

Publications (1)

Publication Number Publication Date
CN101636164A true CN101636164A (zh) 2010-01-27

Family

ID=39476533

Family Applications (2)

Application Number Title Priority Date Filing Date
CN200780049235A Pending CN101636164A (zh) 2006-12-05 2007-12-05 干眼症的治疗
CN200780049245A Pending CN101636165A (zh) 2006-12-05 2007-12-05 用睾酮和孕激素治疗干眼症

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN200780049245A Pending CN101636165A (zh) 2006-12-05 2007-12-05 用睾酮和孕激素治疗干眼症

Country Status (12)

Country Link
US (3) US20080132475A1 (enExample)
EP (2) EP2124958A4 (enExample)
JP (2) JP2010511730A (enExample)
KR (2) KR20090104813A (enExample)
CN (2) CN101636164A (enExample)
AU (1) AU2009202711A1 (enExample)
BR (2) BRPI0720172A2 (enExample)
CA (2) CA2671698A1 (enExample)
EA (2) EA200900663A1 (enExample)
IL (1) IL199094A0 (enExample)
MX (2) MX2009005994A (enExample)
WO (2) WO2008070728A2 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103415292A (zh) * 2011-01-26 2013-11-27 阿勒根公司 用于治疗眼科病症的雄性激素组合物
CN105188708A (zh) * 2013-03-15 2015-12-23 格利亚有限责任公司 颅部的药物递送
CN107427525A (zh) * 2015-04-03 2017-12-01 参天制药株式会社 以诺龙或其酯、美替诺龙或其酯作为有效成分的干眼症治疗剂
CN111956803A (zh) * 2014-10-20 2020-11-20 奥伊斯特普安生物制药公司 治疗眼部病状的方法

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5894364B2 (ja) * 2007-08-16 2016-03-30 ザ スキーペンズ アイ リサーチ インスティチュート インコーポレイテッド 眼および付属器組織の炎症を処置するための治療組成物
US20100016264A1 (en) * 2007-12-05 2010-01-21 Connor Charles G Treatment for dry eye using testosterone and progestagen
US20110144077A1 (en) * 2008-08-05 2011-06-16 Thomas Cotter Treatment of retinal degeneration
EP3936133A1 (en) 2011-11-23 2022-01-12 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
MX362185B (es) * 2012-07-27 2019-01-08 Glia Llc Composiciones y tratamiento para enfermedades y trastornos del ojo.
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
AR100562A1 (es) 2014-05-22 2016-10-12 Therapeuticsmd Inc Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
MX2016013693A (es) 2014-07-29 2017-10-31 Therapeuticsmd Inc Crema transdermica.
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
RU2018133932A (ru) 2016-04-01 2020-05-12 Терапьютиксмд, Инк. Фармацевтическая композиция стероидного гормона
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
EP3509585B1 (en) 2016-09-07 2023-11-01 Glia, LLC Treatment of symptoms related to neurodegenerative disorders through pharmacological dermal activation of cranial nerves
TW202131927A (zh) * 2019-11-13 2021-09-01 美商葛莉亞有限責任公司 睾固酮組合物
WO2023107796A1 (en) * 2021-12-11 2023-06-15 The Regents Of The University Of California Ophthalmic formulations for macular degeneration

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2861920A (en) * 1954-05-04 1958-11-25 Upjohn Co Therapeutic suspensions of steroids containing pvp and/or pva
JPS59184135A (ja) * 1983-04-04 1984-10-19 Teijin Ltd グリセリンピログルタミン酸エステル類を含有する医薬品組成物
US4617299A (en) * 1983-12-19 1986-10-14 Knepper Paul A Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension
DE3514724A1 (de) * 1985-04-24 1986-10-30 Albin F. Dr. 4200 Oberhausen Jereb Salbe zur verbeugung und behandlung von augen- und hauterkrankungen
US4914088A (en) * 1987-04-02 1990-04-03 Thomas Glonek Dry eye treatment solution and method
US5041434A (en) * 1991-08-17 1991-08-20 Virginia Lubkin Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
USRE34578E (en) * 1990-05-07 1994-04-05 Lubkin; Virginia Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
ZA912797B (en) * 1990-05-29 1992-12-30 Boston Ocular Res Dry eye treatment process and solution
US6107289A (en) * 1992-04-21 2000-08-22 The Schepens Eye Research Institute, Inc. Ocular therapy in keratoconjunctivitis sicca using topically applied androgens or TGF-β
US5958912A (en) * 1992-04-21 1999-09-28 The Schepens Eye Research Institute, Inc. Ocular therapy in keratoconjunctivitis sicca using topically applied androgens of TGF-β
ES2139005T3 (es) * 1992-04-21 2000-02-01 Schepens Eye Res Inst Terapia ocular con androgeno en el sindrome de sjogren.
US5688765A (en) * 1992-04-21 1997-11-18 The Schepens Eye Research Institute, Inc. Ocular therapy in Sjogren's syndrome using topically applied androgensor TGF-β
US5366739A (en) * 1992-08-06 1994-11-22 Deo Corporation Method of ophthalmic drug delivery
CA2142103C (en) * 1992-08-28 2003-07-08 Haim Aviv Submicron emulsions as ocular drug delivery vehicles
WO1997020578A1 (en) * 1995-12-04 1997-06-12 University Of Miami Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance
CA2261263C (en) * 1996-07-22 2008-10-07 The Victoria University Of Manchester Use of sex steroid function modulators to treat wounds and fibrotic disorders
ATE293960T1 (de) * 1997-02-28 2005-05-15 Minnesota Mining & Mfg Transdermale vorrichtung zur verabreichungvon von testosteron
US5869090A (en) * 1998-01-20 1999-02-09 Rosenbaum; Jerry Transdermal delivery of dehydroepiandrosterone
FR2774587B1 (fr) * 1998-02-09 2000-03-10 Oreal Utilisation d'une microdispersion de cire dans une composition cosmetique ou dermatologique
US6348210B1 (en) * 1998-11-13 2002-02-19 Alza Corporation Methods for transdermal drug administration
US6117446A (en) * 1999-01-26 2000-09-12 Place; Virgil A. Drug dosage unit for buccal administration of steroidal active agents
CA2376797C (en) * 1999-06-11 2011-03-22 Watson Pharmaceuticals, Inc. Administration of non oral androgenic steroids to women
WO2001041806A1 (en) * 1999-12-07 2001-06-14 Rohto Pharmaceutical Co., Ltd. Ophthalmic compositions
US6630175B1 (en) * 2000-06-29 2003-10-07 Johnson & Johnson Consumer Companies, Inc. Method of reducing eye irritation
AU2002245104B2 (en) * 2000-12-11 2006-08-17 Testocreme, Llc Topical testosterone formulations and associated methods
US6659985B2 (en) * 2002-01-30 2003-12-09 Southern College Of Optometry Method to use transdermal administration of androgens to the adnexa of the eye
WO2004045510A2 (en) * 2002-11-15 2004-06-03 Panaseca, Inc. Methods and compositions for alleviating dry eyes
US20060111318A1 (en) * 2003-04-18 2006-05-25 Advanced Medicine Research Institute Agent for treating eye diseases
US6984628B2 (en) * 2003-07-15 2006-01-10 Allergan, Inc. Ophthalmic compositions comprising trefoil factor family peptides
US7960350B2 (en) * 2003-10-24 2011-06-14 Ader Enterprises, Inc. Composition and method for the treatment of eye disease
US20050202097A1 (en) * 2004-03-12 2005-09-15 Melbj Holdings, Llc, Florida Lubricant for the ocular surface
US20050234018A1 (en) * 2004-04-15 2005-10-20 Allergan, Inc. Drug delivery to the back of the eye
US20060110428A1 (en) * 2004-07-02 2006-05-25 Eugene Dejuan Methods and devices for the treatment of ocular conditions
JP2008530127A (ja) * 2005-02-09 2008-08-07 マクサイト， インコーポレイテッド 眼の処置のための処方物
US20100016264A1 (en) * 2007-12-05 2010-01-21 Connor Charles G Treatment for dry eye using testosterone and progestagen

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103415292A (zh) * 2011-01-26 2013-11-27 阿勒根公司 用于治疗眼科病症的雄性激素组合物
CN105188708A (zh) * 2013-03-15 2015-12-23 格利亚有限责任公司 颅部的药物递送
CN105188708B (zh) * 2013-03-15 2019-06-28 格利亚有限责任公司 颅部的药物递送
CN111956803A (zh) * 2014-10-20 2020-11-20 奥伊斯特普安生物制药公司 治疗眼部病状的方法
CN107427525A (zh) * 2015-04-03 2017-12-01 参天制药株式会社 以诺龙或其酯、美替诺龙或其酯作为有效成分的干眼症治疗剂

Also Published As

Publication number Publication date
EP2101785A2 (en) 2009-09-23
US20210008079A1 (en) 2021-01-14
BRPI0720172A2 (pt) 2014-01-07
EA200900662A1 (ru) 2009-12-30
EP2101785A4 (en) 2009-12-30
KR20090104814A (ko) 2009-10-06
WO2008070726A2 (en) 2008-06-12
CA2671769A1 (en) 2008-06-12
MX2009005993A (es) 2009-12-14
AU2009202711A1 (en) 2009-07-23
CN101636165A (zh) 2010-01-27
WO2008070726A3 (en) 2008-08-21
KR20090104813A (ko) 2009-10-06
IL199094A0 (en) 2010-03-28
CA2671698A1 (en) 2008-06-12
EP2124958A2 (en) 2009-12-02
EA200900663A1 (ru) 2009-12-30
JP2010511730A (ja) 2010-04-15
WO2008070728A2 (en) 2008-06-12
WO2008070728A3 (en) 2008-08-07
US20080132475A1 (en) 2008-06-05
EP2124958A4 (en) 2009-12-30
BRPI0719918A2 (pt) 2014-03-04
US20140113889A1 (en) 2014-04-24
JP2010511729A (ja) 2010-04-15
MX2009005994A (es) 2009-12-14

Similar Documents

Publication Publication Date Title
CN101636164A (zh) 干眼症的治疗
US20100016264A1 (en) Treatment for dry eye using testosterone and progestagen
TWI335819B (en) Use of oculosurface selective glucocorticoid in the treatment of dry eye
JP6296977B2 (ja) 経皮薬物送達システムおよびその使用方法
JP6209777B2 (ja) 眼の疾病及び疾患のための組成物及び治療
US6096733A (en) Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
Samsioe Transdermal hormone therapy: gels and patches
KR20180084149A (ko) 프로게스틴/에스트라디올 경피 젤
JP2024056898A (ja) 眼周囲分泌腺におけるまたは眼表面での異常な炎症を処置するための組成物および使用方法
US20020081338A1 (en) Composition for treating dry eye
US20180263901A1 (en) Time-release and micro-dose formulations for topical application of estrogen and estrogen analogs or other estrogen receptor modulators in the treatment of dry eye syndrome, and methods of preparation and application
US20080287408A1 (en) Endometriosis treatment
Moghadam et al. Advances in menopausal hormonal therapy delivery systems: a comparative review
TWI632913B (zh) 用於眼部疾病或異常之組合物及其治療方法
WO2025144421A1 (en) Aqueous nanomicelle ophthalmic formulations containing difluprednate
HK40031764B (zh) 用於治疗眼周分泌腺中或眼表上的异常发炎的组合物和方法
HK40028751A (en) Ophthalmic compositions comprising f6h8
Sitruk-Ware et al. Patent: Nestorone®/estradiol transdermal gel

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20100127